HU KAI
Member of the Professional Committee of Geriatric Oncology, Chinese Geriatric Society.
Member of the First Chinese T-cell Lymphoma Working Group of the Professional Committee of Oncohematology of the Chinese Anti-Cancer Association.
Member of the Professional Committee on Hematopoietic Cell Transplantation and Cell Therapy, Chinese Association for Medical Education.
Chairman of the Expert Committee on Accurate Diagnosis and Treatment of Blood Tumors, Beijing Health Protection Association.
Member of the Professional Committee of Hematology of Beijing Research Association.
Member of the Professional Committee of Clinical Research of Beijing Cancer Association.
Conducts in-depth research in the field of immunotherapy, biomarkers, is well acquainted with the latest international standards of diagnostics and treatment of lymphoma. Participates in 20 international and national clinical studies on diagnostics and treatment of lymphomas and multiple myeloma.
Specialization:
multidisciplinary complex treatment of hematological malignancies
early diagnosis of lymphoma, multiple myeloma, leukemia
complex standardized treatment based on drug chemotherapy, molecular targeted therapy, autologous/allogeneic hematopoietic stem cell transplantation and biological therapy
Read moreHU KAI
Member of the Professional Committee of Geriatric Oncology, Chinese Geriatric Society.
Member of the First Chinese T-cell Lymphoma Working Group of the Professional Committee of Oncohematology of the Chinese Anti-Cancer Association.
Member of the Professional Committee on Hematopoietic Cell Transplantation and Cell Therapy, Chinese Association for Medical Education.
Chairman of the Expert Committee on Accurate Diagnosis and Treatment of Blood Tumors, Beijing Health Protection Association.
Member of the Professional Committee of Hematology of Beijing Research Association.
Member of the Professional Committee of Clinical Research of Beijing Cancer Association.
Conducts in-depth research in the field of immunotherapy, biomarkers, is well acquainted with the latest international standards of diagnostics and treatment of lymphoma. Participates in 20 international and national clinical studies on diagnostics and treatment of lymphomas and multiple myeloma.
Specialization:
multidisciplinary complex treatment of hematological malignancies
early diagnosis of lymphoma, multiple myeloma, leukemia
complex standardized treatment based on drug chemotherapy, molecular targeted therapy, autologous/allogeneic hematopoietic stem cell transplantation and biological therapy